• Je něco špatně v tomto záznamu ?

Long-term outcomes of the pentaspline pulsed-field ablation catheter for the treatment of paroxysmal atrial fibrillation: results of the prospective, multicentre FARA-Freedom Study

A. Metzner, M. Fiala, J. Vijgen, A. Ouss, M. Gunawardene, J. Hansen, J. Kautzner, B. Schmidt, M. Duytschaever, T. Reichlin, Y. Blaauw, P. Sommer, A. Vanderper, AB. Achyutha, M. Johnson, JD. Raybuck, P. Neuzil

. 2024 ; 26 (3) : . [pub] 20240301

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu multicentrická studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24006850

Grantová podpora
Boston Scientific

AIMS: Pulmonary vein isolation (PVI) is a well-established strategy for the treatment of paroxysmal atrial fibrillation (PAF). Despite randomized controlled trials and real-world data showing the promise of pulsed-field ablation (PFA) for this treatment, long-term efficacy and safety data demonstrating single-procedure outcomes off antiarrhythmic drugs remain limited. The aim of the FARA-Freedom Study was to evaluate the long-term efficacy and safety of PFA using the pentaspline catheter for PAF. METHODS AND RESULTS: FARA-Freedom, a prospective, non-randomized, multicentre study, enrolled patients with PAF undergoing de novo PVI with PFA, who were followed for 12 months with weekly transtelephonic monitoring and a 72-h Holter ECG at 6 and 12 months. The primary safety endpoint was a composite of device- or procedure-related serious adverse events out to 7 days post-ablation and PV stenosis or atrioesophageal (AE) fistula out to 12 months. Treatment success is a composite of acute PVI and chronic success, which includes freedom from any documented atrial tachyarrhythmia longer than 30 s, use of antiarrhythmic drugs or cardioversion after a 3-month blanking period, or use of amiodarone or repeat ablation at any time. The study enrolled 179 PAF patients (62 ± 10 years, 39% female) at 13 centres. At the index procedure, all PVs were successfully isolated with the pentaspline PFA catheter. Procedure and left atrial dwell times, with a 20-min waiting period, were 71.9 ± 17.6 and 41.0 ± 13.3 min, respectively. Fluoroscopy time was 11.5 ± 7.4 min. Notably, monitoring compliance was high, with 88.4 and 90.3% with weekly events and 72-h Holter monitors, respectively. Freedom from the composite primary effectiveness endpoint was 66.6%, and 41 patients had atrial tachyarrhythmia recurrence, mostly recurrent atrial fibrillation (31 patients). The composite safety endpoint occurred in two patients (1.1%), one tamponade and one transient ischaemic attack. There was no coronary spasm, PV stenosis, or AE fistula. There were four cases of transient phrenic nerve palsy, but all resolved during the index procedure. CONCLUSION: In this prospective, non-randomized, multicentre study, PVI using a pentaspline PFA catheter was effective in treating PAF patients despite rigourous endpoint definitions and high monitoring compliance and demonstrated favourable safety. REGISTRATION: Clinical Trials.gov Identifier: NCT05072964 (sponsor: Boston Scientific Corporation).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24006850
003      
CZ-PrNML
005      
20240423155531.0
007      
ta
008      
240412s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/europace/euae053 $2 doi
035    __
$a (PubMed)38385529
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Metzner, Andreas $u Klinik für Kardiologie, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, Gebäude Ost 70, 20246 Hamburg, Germany $1 https://orcid.org/0000000268186396
245    10
$a Long-term outcomes of the pentaspline pulsed-field ablation catheter for the treatment of paroxysmal atrial fibrillation: results of the prospective, multicentre FARA-Freedom Study / $c A. Metzner, M. Fiala, J. Vijgen, A. Ouss, M. Gunawardene, J. Hansen, J. Kautzner, B. Schmidt, M. Duytschaever, T. Reichlin, Y. Blaauw, P. Sommer, A. Vanderper, AB. Achyutha, M. Johnson, JD. Raybuck, P. Neuzil
520    9_
$a AIMS: Pulmonary vein isolation (PVI) is a well-established strategy for the treatment of paroxysmal atrial fibrillation (PAF). Despite randomized controlled trials and real-world data showing the promise of pulsed-field ablation (PFA) for this treatment, long-term efficacy and safety data demonstrating single-procedure outcomes off antiarrhythmic drugs remain limited. The aim of the FARA-Freedom Study was to evaluate the long-term efficacy and safety of PFA using the pentaspline catheter for PAF. METHODS AND RESULTS: FARA-Freedom, a prospective, non-randomized, multicentre study, enrolled patients with PAF undergoing de novo PVI with PFA, who were followed for 12 months with weekly transtelephonic monitoring and a 72-h Holter ECG at 6 and 12 months. The primary safety endpoint was a composite of device- or procedure-related serious adverse events out to 7 days post-ablation and PV stenosis or atrioesophageal (AE) fistula out to 12 months. Treatment success is a composite of acute PVI and chronic success, which includes freedom from any documented atrial tachyarrhythmia longer than 30 s, use of antiarrhythmic drugs or cardioversion after a 3-month blanking period, or use of amiodarone or repeat ablation at any time. The study enrolled 179 PAF patients (62 ± 10 years, 39% female) at 13 centres. At the index procedure, all PVs were successfully isolated with the pentaspline PFA catheter. Procedure and left atrial dwell times, with a 20-min waiting period, were 71.9 ± 17.6 and 41.0 ± 13.3 min, respectively. Fluoroscopy time was 11.5 ± 7.4 min. Notably, monitoring compliance was high, with 88.4 and 90.3% with weekly events and 72-h Holter monitors, respectively. Freedom from the composite primary effectiveness endpoint was 66.6%, and 41 patients had atrial tachyarrhythmia recurrence, mostly recurrent atrial fibrillation (31 patients). The composite safety endpoint occurred in two patients (1.1%), one tamponade and one transient ischaemic attack. There was no coronary spasm, PV stenosis, or AE fistula. There were four cases of transient phrenic nerve palsy, but all resolved during the index procedure. CONCLUSION: In this prospective, non-randomized, multicentre study, PVI using a pentaspline PFA catheter was effective in treating PAF patients despite rigourous endpoint definitions and high monitoring compliance and demonstrated favourable safety. REGISTRATION: Clinical Trials.gov Identifier: NCT05072964 (sponsor: Boston Scientific Corporation).
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    12
$a fibrilace síní $x chirurgie $7 D001281
650    _2
$a prospektivní studie $7 D011446
650    _2
$a antiarytmika $7 D000889
650    _2
$a stenóza $x chirurgie $7 D003251
650    _2
$a výsledek terapie $7 D016896
650    12
$a katetrizační ablace $x metody $7 D017115
650    _2
$a tachykardie $x chirurgie $7 D013610
650    12
$a píštěle $x chirurgie $7 D005402
650    12
$a venae pulmonales $x chirurgie $7 D011667
650    _2
$a recidiva $7 D012008
655    _2
$a multicentrická studie $7 D016448
655    _2
$a časopisecké články $7 D016428
700    1_
$a Fiala, Martin $u Department of Internal Medicine and Cardiology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Vijgen, Johan $u Division of Electrophysiology, Jessa Ziekenhuis, Hasselt, Belgium $1 https://orcid.org/0000000349284836
700    1_
$a Ouss, Alexandre $u Department of Cardiology, Catharina Ziekenhuis, Eindhoven, The Netherlands $1 https://orcid.org/000000017405822X
700    1_
$a Gunawardene, Melanie $u Department of Cardiology and Internal Intensive Care Medicine, Asklepios Klinik St Georg, Hamburg, Germany $1 https://orcid.org/0000000175617185
700    1_
$a Hansen, Jim $u Department of Cardiology, Gentofte Hospital, Hellerup, Denmark $1 https://orcid.org/0000000166009006
700    1_
$a Kautzner, Josef $u Department of Cardiology, Institute for Clinical and Experimental Medicine-IKEM, Prague, Czech Republic $1 https://orcid.org/0000000216326182 $7 xx0037112
700    1_
$a Schmidt, Boris $u Cardioangiologisches Centrum Bethanien, Academic Teaching Hospital of Goethe University of Frankfurt, Frankfurt, Germany $1 https://orcid.org/0000000153479906
700    1_
$a Duytschaever, Mattias $u Department or Cardiology, AZ SINT-Jan AV, Bruges, Belgium $1 https://orcid.org/0000000184510013 $7 xx0257832
700    1_
$a Reichlin, Tobias $u Department of Rhythmology and Cardiac Electrophysiology, Inselspital University Hospital Bern, University of Bern, Bern, Switzerland $1 https://orcid.org/0000000271978415
700    1_
$a Blaauw, Yuri $u Department of Cardiology, University Medical Center, Groningen, The Netherlands
700    1_
$a Sommer, Philipp $u Department of Cardiology and Rhythmology, Hdz Nrw, Bad Oeynhausen, Gemany $1 https://orcid.org/0000000230378704
700    1_
$a Vanderper, Annelies $u AF Solutions, Boston Scientific Corp, St. Paul, MN, USA
700    1_
$a Achyutha, Anitha B $u AF Solutions, Boston Scientific Corp, St. Paul, MN, USA
700    1_
$a Johnson, Madeline $u AF Solutions, Boston Scientific Corp, St. Paul, MN, USA $1 https://orcid.org/0000000175242846
700    1_
$a Raybuck, Jonathan D $u AF Solutions, Boston Scientific Corp, St. Paul, MN, USA
700    1_
$a Neuzil, Petr $u Department of Cardiology, Nemocnice Na Homolce Hospital, Prague, Czech Republic $1 https://orcid.org/0000000343348165
773    0_
$w MED00149837 $t Europace $x 1532-2092 $g Roč. 26, č. 3 (2024)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38385529 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155528 $b ABA008
999    __
$a ok $b bmc $g 2081056 $s 1216617
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 26 $c 3 $e 20240301 $i 1532-2092 $m Europace $n Europace $x MED00149837
GRA    __
$p Boston Scientific
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace